Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin

This study has been completed.
Information provided by (Responsible Party):
University of California, San Francisco Identifier:
First received: September 14, 2005
Last updated: August 7, 2012
Last verified: August 2012
The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. Previously, we have recruited a cohort of healthy volunteers (Studies of Pharmacogenetics in Ethnically-diverse Populations, or SOPHIE) and have resequenced the coding region of a number of membrane transporter genes to identify genetic polymorphisms in these genes. We plan to take a genotype-to-phenotype approach to study the influence of specific polymorphisms in the intestinal transporters, such as the novel organic cation transporters 1 and 2 (OCTN1 and OCTN2) genes on the bioavailability of gabapentin in healthy subjects. Eligible subjects will have a single inpatient study visit, during which they will take a single dose of gabapentin, and provide blood and urine samples over the course of 36 hours (5 terminal elimination gabapentin half-lives) for pharmacokinetic analysis.

Condition Intervention
Drug: Gabapentin

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin

Resource links provided by NLM:

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin [ Time Frame: Gabapentin ] [ Designated as safety issue: No ]
    To evaluate the bioavailability of Gabapentin in healthy individuals

Enrollment: 30
Study Start Date: September 2005
Study Completion Date: August 2008
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Subjects will take a single dose of 400 mg of gabapentin
Drug: Gabapentin
Subjects will take a single dose of 400 mg of gabapentin

Detailed Description:
Detailed description pending

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects must have previously participated in the "SOPHIE" study.
  • Subjects will be between the ages of 18 and 40 years old
  • Subjects will have been selected as healthy by medical history questionnaire and screening blood work (CBC, Comprehensive Metabolic panel).
  • Subjects will be taking no regular medications and will have normal renal function.

Exclusion Criteria:

  • Pregnant
  • Have a new history indicating they are no longer healthy; Individuals with anemia (hemoglobin < 12 g/dL), an elevation in liver enzymes to higher than double the respective normal value, or elevated creatinine concentrations (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL), will be excluded.
  • Taking a medication that could confound study results
  • Do not consent to participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00187707

United States, California
San Francisco General Hospital
San Francisco, California, United States, 94143
Sponsors and Collaborators
University of California, San Francisco
Principal Investigator: Kathleen Giacomini, PhD University of California, San Francisco
  More Information

Responsible Party: University of California, San Francisco Identifier: NCT00187707     History of Changes
Other Study ID Numbers: 1003 
Study First Received: September 14, 2005
Last Updated: August 7, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Gamma-Aminobutyric Acid
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents
GABA Agents processed this record on October 27, 2016